 Uniqure NV NASDAQ: QURE shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQure said the FDA has placed its Hemophilia B gene therapy program, including the late-stage HOPE-B study, on clinical hold. 